Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 8 clients • 9 examiners • 6 art units • 0 of 9 (0%) have an AI response strategy ready
Anderson Patent Law Firm LLC specializes in Biotechnology & Pharmaceuticals, with a history of 659 career applications. The firm achieves a resolved allowance rate of 83.17 percent. Prosecution typically involves 4.14 office actions per allowance, a figure that highlights the iterative nature of securing patents in the life sciences sector. These metrics offer a view of the firm's historical performance and its experience with biotechnological filings.
The firm is currently managing 5 pending office actions. Given the 659 career applications, these 5 pending matters represent the firm's current active engagement with the USPTO. The 83.17 percent allowance rate and the 4.14 office actions per allowance provide a statistical profile of the firm's historical effectiveness. Practitioners can use these data points to estimate the likely effort and success rate for applications handled by the firm within these technical fields.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (11%) |
| §101 + other | 1 (11%) |
| §103 only | 3 (33%) |
| §112 only | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAWKINS, DOMINIC E | 1 | 86.9% | +12.1% |
| WESTERBERG, NISSA M | 1 | 23.4% | +37.1% |
| KUYKENDALL, ALYSSA LEE | 1 | 20.8% | +95.0% |
| STUBBS, JOHN THOMAS | 1 | — | — |
| PENDLETON, DIONNE | 1 | 69.8% | +15.7% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| PRAGANI, RAJAN | 1 | 53.3% | +70.0% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627785 | Novel Erwinia Strains and Related Methods | FAY, ZOHREH ALEMZADEH | 126d overdue |
| 16328853 | Provision of a Therapeutically Active Cell Product | CONNORS, ALEXANDRA F | 10d overdue |
| 18938433 | Method and Apparatus for Noninvasive Determination of Utilization | HAWKINS, DOMINIC E | — |
| 18570180 | Contrast agent for magnetic resonance imaging | WESTERBERG, NISSA M | — |
| 18555300 | System and process for producing synthetic fuels without emitting carbon dioxide | KUYKENDALL, ALYSSA LEE | — |
| 18039356 | Selection Methods | STUBBS, JOHN THOMAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026990 | Method and system for contextual notification | PENDLETON, DIONNE | 120d overdue |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | PRAGANI, RAJAN | 104d overdue |
| 16328853 | Provision of a Therapeutically Active Cell Product | CONNORS, ALEXANDRA F | 10d overdue |
| 17409066 | Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration | HAQ, SHAFIQUL | 79d |
| 18938433 | Method and Apparatus for Noninvasive Determination of Utilization | HAWKINS, DOMINIC E | — |
| 18570180 | Contrast agent for magnetic resonance imaging | WESTERBERG, NISSA M | — |
| 18555300 | System and process for producing synthetic fuels without emitting carbon dioxide | KUYKENDALL, ALYSSA LEE | — |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| 2689 | 1 |
| 1617 | 1 |
| 1614 | 1 |
| 1678 | 1 |
| 1634 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18938433 | Method and Apparatus for Noninvasive Determination of Utilization | Elemental Machines, Inc. | HAWKINS, DOMINIC E | §103§112Other | Non-Final OA | — | Pending | Nov 06, 2024 | |
| 18570180 | Contrast agent for magnetic resonance imaging | Betavist GmbH | WESTERBERG, NISSA M | §102§103§112 | Non-Final OA | — | Pending | Dec 14, 2023 | |
| 18555300 | System and process for producing synthetic fuels without emitting carbon dioxide | Edl Anlagenbau Gesellschaft Mbh | KUYKENDALL, ALYSSA LEE | 1692 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18039356 | Selection Methods | Agriculture Victoria Services Pty Ltd | STUBBS, JOHN THOMAS | §101§103 | Non-Final OA | — | Pending | May 30, 2023 | |
| 18026990 | Method and system for contextual notification | Elemental Machines, Inc. | PENDLETON, DIONNE | 2689 | §103 | Non-Final OA | 120d overdue | Pending | Mar 17, 2023 |
| 17627785 | Novel Erwinia Strains and Related Methods | Geoffrey Gardiner Dairy Foundation Limited | FAY, ZOHREH ALEMZADEH | 1617 | §101 | Non-Final OA | 126d overdue | Pending | Jan 17, 2022 |
| 17627751 | Cosmetic Preparations Comprising Natural Activators | UNIVERSITÄT BASEL | PRAGANI, RAJAN | 1614 | §103 | Final Rejection | 104d overdue | Pending | Jan 17, 2022 |
| 17409066 | Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration | Maintect GmbH | HAQ, SHAFIQUL | 1678 | §112 | Final Rejection | 79d | Pending | Aug 23, 2021 |
| 16328853 | Provision of a Therapeutically Active Cell Product | Pdi Pharm Development International AG | CONNORS, ALEXANDRA F | 1634 | §103 | Non-Final OA | 10d overdue | Pending | Feb 27, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial